BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
210 hedge funds and large institutions have $3.8B invested in bluebird bio in 2015 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 71 increasing their positions, 68 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
4% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 68
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Holders
210
Holding in Top 10
4
Calls
$97.3M
Puts
$70M
Top Buyers
| 1 | +$155M | |
| 2 | +$74.7M | |
| 3 | +$66.5M | |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$65.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$48.8M |
Top Sellers
| 1 | -$111M | |
| 2 | -$36.9M | |
| 3 | -$27.5M | |
| 4 |
DM
Deerfield Management
New York
|
-$26.5M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$21.2M |